Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-0900

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-0900). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)

Chemical structure of donepezil hydrochloride depicted as a molecular formula diagram showing its chemical bonds and arrangement.*

FDA Label Image

Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)

A line chart showing ADAS-cog change from baseline (mean ± SE) over 30 weeks of drug treatment with donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The chart depicts cognitive function improvement with donepezil doses, compared to decline in the placebo group over time, including a placebo period at the end.*

FDA Label Image

Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)

Line graph showing cumulative percentage of patients versus change from baseline in ADAS-cog scores for donepezil hydrochloride 10 mg/day, donepezil hydrochloride 5 mg/day, and placebo treatment groups. The graph includes markers for 7 points, 4 points, and no change, and a table summarizing percentage changes for each group at specific points (-7, -4, 2, 9).*

FDA Label Image

Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)

A bar graph showing the percentage of patients by CIBIC-plus Rating categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. Data are compared across three groups: donepezil hydrochloride 10 mg/day, donepezil hydrochloride 5 mg/day, and placebo.*

FDA Label Image

Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)

A line graph depicting ADAS-cog mean change from baseline with standard error bars over 15 weeks of drug treatment, comparing donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis shows weeks of drug treatment, including a placebo period after 12 weeks. The y-axis represents ADAS-cog change, with clinical improvement above baseline and clinical decline below baseline. Donepezil groups show greater improvement than placebo.*

FDA Label Image

Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)

A line graph showing cumulative percentage of patients versus change from baseline in ADAS-cog scores, comparing donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis ranges from -15 to 10 in change from baseline; the y-axis shows cumulative percentage of patients from 0 to 100%. A table inset summarizes percentage of patients experiencing declines or no change in ADAS-cog by treatment group.*

FDA Label Image

Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)

A bar chart labeled 'CIBIC-plus Rating' showing the percentage of patients on the vertical axis and categories from 'Markedly Improved' to 'Markedly Worse' on the horizontal axis. It compares three groups: Aricept 10 mg/day, Aricept 5 mg/day, and Placebo, with black, dark gray, and light gray bars respectively, depicting patient outcome distributions across these categories.*

FDA Label Image

Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)

A line graph showing the change from baseline SIB (Severe Impairment Battery) scores over 6 months of drug treatment. It compares donepezil hydrochloride 10 mg/day and placebo, indicating clinical improvement versus clinical decline on the vertical axis and months of treatment on the horizontal axis.*

FDA Label Image

Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)

A cumulative percentage graph showing the change from baseline in SIB (Severe Impairment Battery) scores for patients treated with donepezil hydrochloride 10 mg/day compared to placebo. The graph plots cumulative percentage of patients on the y-axis against SIB change from baseline on the x-axis, illustrating the distribution of treatment responses over time.*

FDA Label Image

Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)

A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. It compares donepezil hydrochloride 10 mg/day (solid circles) with placebo (open squares), illustrating clinical improvement versus decline. The y-axis represents change from baseline, and the x-axis represents months of treatment (0, 3, 6). Error bars indicate standard error.*

FDA Label Image

Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)

A cumulative percentage of patients graph compares donepezil hydrochloride 10 mg/day and placebo. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients, illustrating patient response distributions for both treatments in a clinical setting.*

FDA Label Image

Label Image (Lbl713350900)

Donepezil HCl 10mg tablet label from Bryant Ranch Prepack, showing it is a yellow round tablet with identifier HH210. The label indicates comparison to Aricept 10mg tablet by Zhejiang Huahai Pharmaceutical Co. Storage instructions specify room temperature (20°-25°C). The NDC number displayed is 71335-09001 and the package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.